Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain CLVS message board posts where the ticker symbol CLVS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest CLVS SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000904454-18-000370 Size: 9 KB
2018-05-23
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-18-004440 (34 Act)  Size: 7 MB
2018-05-09 001-35347
18817588
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001157523-18-001040 (34 Act)  Size: 86 KB
2018-05-08 001-35347
18814521
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001193125-18-139074 (34 Act)  Size: 63 KB
2018-04-27 001-35347
18784551
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001193125-18-139043 (34 Act)  Size: 912 KB
2018-04-27 001-35347
18784431
8-K  Documents Current report, items 1.01, 2.03, 8.01, and 9.01
Acc-no: 0001193125-18-122697 (34 Act)  Size: 1 MB
2018-04-19 001-35347
18764128
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-119822 (33 Act)  Size: 486 KB
2018-04-17 333-215400
18759245
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-119811 (33 Act)  Size: 828 KB
2018-04-17 333-215400
18759178
FWP  Documents Filing under Securities Act Rules 163/433 of free writing prospectuses
Acc-no: 0001193125-18-119345 (34 Act)  Size: 51 KB
2018-04-17 333-215400
18758077
FWP  Documents Filing under Securities Act Rules 163/433 of free writing prospectuses
Acc-no: 0001193125-18-118972 (34 Act)  Size: 16 KB
2018-04-17 333-215400
18757780
More CLVS SEC Filings


Related news from
Wed, 16 May 2018
15:55:00 +0000
Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting
Clovis Oncology, Inc. today announced that seven abstracts highlighting progress in the Rubraca preclinical research and clinical development program will be presented at the 2018 American Society of Clinical Oncology Annual Meeting taking place June 1-5 in Chicago.
Mon, 14 May 2018
11:31:02 +0000
How Lynparza Performed in 1Q18
On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza. In 1Q18, Merck reported $33 million as its share of the Lynparza alliance revenues, of which $24 million were earned in US markets, while the remaining $9.0 million were reported from international markets. Lynparza is currently the leading PARP inhibitor in terms of new and total prescriptions for its approved label in ovarian cancer and breast cancer indications.
Thu, 10 May 2018
19:23:37 +0000
Former Biotech Darlings Tesaro, Clovis Pin Hopes on 2018 Rebound
Considered a year ago to be among the top takeover targets in biotech, Tesaro Inc. and Clovis Oncology Inc. have so far failed to live up to their hype on Wall Street. Shares of Tesaro have fallen 71 percent since the U.S. Food and Drug Administration approved its ovarian cancer drug Zejula in March 2017. Clovis is down 32 percent over that time as its competing therapy has also struggled to meet sales estimates.
Thu, 10 May 2018
13:24:07 +0000
Edited Transcript of CLVS earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 Clovis Oncology Inc Earnings Call
Wed, 09 May 2018
22:08:00 +0000
CORRECTING and REPLACING Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018
Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time .
Wed, 09 May 2018
15:09:03 +0000
Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat
Clovis (CLVS) witnesses wider year-over-year loss in the first quarter. However, the company's revenues beat estimates. Rubraca sales increase.
Wed, 09 May 2018
11:35:00 +0000
Consolidated Research: 2018 Summary Expectations for Catalent, MGIC Investment, United Rentals, Clovis Oncology, Pure Storage, and Chipotle Mexican Grill — Fundamental Analysis, Key Performance Indications
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catalent, ...
Tue, 08 May 2018
21:27:32 +0000
Clovis: 1Q Earnings Snapshot
The Boulder, Colorado-based company said it had a loss of $1.54 per share. Losses, adjusted for stock option expense, were $1.30 per share. The results beat Wall Street expectations. The average estimate ...
Tue, 08 May 2018
20:05:00 +0000
Clovis Oncology Announces First Quarter 2018 Operating Results
Clovis Oncology, Inc. reported financial results for the quarter ended March 31, 2018, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for 2018.
Tue, 08 May 2018
12:51:16 +0000
How Has Clovis Oncology Inc’s (NASDAQ:CLVS) Earnings Fared Against The Long Term Trend
Understanding how Clovis Oncology Inc (NASDAQ:CLVS) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...
Tue, 01 May 2018
13:38:20 +0000
Is Clovis Oncology Inc’s (NASDAQ:CLVS) Balance Sheet Strong Enough To Weather A Storm?
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Clovis Oncology Inc (NASDAQ:CLVS), with a market cap of US$2.40B, are often out of theRead More...
Tue, 24 Apr 2018
20:15:00 +0000
Clovis Oncology to Announce First Quarter 2018 Financial Results and Host Webcast Conference Call on May 8
Clovis Oncology, Inc. will announce its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m.
Tue, 17 Apr 2018
12:10:00 +0000
Today’s Research Reports on Stocks to Watch: Clovis Oncology and Loxo Oncology
NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Clovis Oncology saw its shares close down over 10% on Monday after announcing that it has commenced two separate underwritten public offerings. Shares of Loxo ...
Tue, 17 Apr 2018
00:54:00 +0000
Clovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock
Clovis Oncology, Inc. announced today the upsizing and pricing of an underwritten public offering of $300 million aggregate principal amount of its 1.25% convertible senior notes due 2025 at a price to the public of 100% of the principal amount of the notes, before underwriting discounts and commissions.
Mon, 16 Apr 2018
10:44:00 +0000
Clovis Oncology Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Clovis Oncology, Inc.  announced today that it has commenced two separate underwritten public offerings of convertible senior notes and common stock.
Fri, 13 Apr 2018
12:04:08 +0000
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $130 million.
Tue, 10 Apr 2018
12:30:00 +0000
Today’s Research Reports on Trending Tickers: Clovis Oncology and Nektar Therapeutics
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
Mon, 09 Apr 2018
13:54:01 +0000
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.
Mon, 09 Apr 2018
12:47:12 +0000
Clovis Oncology (CLVS) Surges: Stock Moves 5.9% Higher
Clovis Oncology (CLVS) shares rose nearly 6% in the last trading session, amid huge volumes.
Mon, 09 Apr 2018
12:30:00 +0000
Today’s Research Reports on Trending Tickers: Clovis Oncology and CVS Health
NEW YORK, NY / ACCESSWIRE / April 9, 2018 / U.S. equities experienced weekly losses last week as rising concerns over a potential trade war continued to pressure markets lower on Friday. The Dow Jones ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I joined almost three years ago and have never been sorry. The search features here are terrific." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards